This program will emphasize the pharmacists’ role to improve medication adherence for patients with mild to severe COPD, and will provide updates about the latest therapeutic options available for the treatment of COPD. This activity will focus on instructing pharmacists about the most recent treatment developments available for patients with COPD. Pharmacists will be able to assist patients with mild to severe COPD understand the nuances between nebulized therapy and inhaled treatments.
At the completion of this application-based activity, participants will be able to:
- Identify available pharmacotherapies that can be prescribed to improve symptoms and decrease exacerbations for patients with COPD.
- Utilize a validated assessment tool to identify patient risk and symptoms and use this information to recommend appropriate medication treatment for patients with COPD.
- Demonstrate and apply treatment plans using self-management principles to facilitate medication treatment adherence for patients with COPD.
- Facilitate the correct use of inhaler and nebulizer devices with proper inhaler technique for patients with COPD and to incorporate a management cycle to regularly follow-up with patients.
Activity type: Application-based
Target Audience: Pharmacists
Learning Level: 2
The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The following archived webinar is approved for 1.0 contact hour of CPE credit (0.1 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-20-324-H01-P.
To obtain credit for completing Community Pharmacist and COPD Treatment Options: Reduce Symptoms, Improve Airflow, and Reduce Exacerbation Risks, participants will need to complete the learning activity in full, complete the assessment with a grade of 70% or better, complete the evaluation questions, and then CLAIM credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.
APhA continuing pharmacy education policy provides you with two opportunities to successfully complete this continuing pharmacy education assessment. Please note that you will not be permitted to submit the assessment a third time. The current policy of the APhA Education Department is not to release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.
Initial release date: September 1, 2020
Expiration date: September 1, 2023 - No credit can be earned after this date
Development and Support
Community Pharmacist and COPD Treatment Options: Reduce Symptoms, Improve Airflow, and Reduce Exacerbation Risks is an activity for pharmacists developed by the American Pharmacists Association and supported by an educational grant from Mylan. ©2020 American Pharmacists Association
Dennis Williams, PharmD, declares that his spouse owns stock in Glaxo-Smith-Kline (GSK).
Suzanne G. Bollmeier, PharmD, FCCP, BCPS, AE-C, Lori A. Wilken, PharmD, BCACP, NCTTP, AE-C, and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For a complete list of APhA staff disclosures, visit the APhA website at www.pharmacist.com/apha-disclosures.
Conflicts of interest have been resolved through content review by Helen Sairany, BA, PharmD, MBA, BCACP, Director of Content Development & Partnership at the American Pharmacists Association.
There is no fee associated with this activity.
Computer and internet access are required to complete this activity. Please visit our website to view the Technology System Requirements in order to have a positive learning experience.
|Activity Number||Credit Amount||Accreditation Period|
|ACPE# 0202-0000-20-324-H01-P||0.1 CEUs||September 01, 2020 - September 01, 2023|